Bibliographic Details
| Title: |
MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. |
| Authors: |
Shih-Feng Cho1,2, Yuli Christine Chang3, Chao-Sung Chang2,4, Sheng-Fung Lin2,5, Yi-Chang Liu2,5, Hui-Hua Hsiao2,5, Jan-Gowth Chang6,7,8 d6781@mail.cmuh.org.tw, Ta-Chih Liu1,2 d730093@cc.kmu.edu.tw |
| Source: |
BMC Cancer. 11/4/2014, Vol. 14, p1-8. 8p. 3 Charts, 2 Graphs. |
| Subject Terms: |
*MULTIPLE myeloma treatment, *NON-coding RNA, *GENETIC overexpression, *TUMOR markers, *CANCER invasiveness |
| Abstract: |
Background: The pathogenesis of multiple myeloma involves complex genetic and epigenetic events. This study aimed to investigate the role and clinical relevance of the long non-coding RNA (lncRNA), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in multiple myeloma. Methods: Bone marrow mononuclear cells were collected for analysis. The samples of multiple myeloma were taken from 45 patients at diagnosis, 61 post-treatment, and 18 who relapsed or had progression. Control samples were collected from 20 healthy individuals. Real-time quantitative reverse transcription polymerase chain reactions were performed to evaluate the expression of MALAT1. The clinical relevance of MALAT1 expression was also explored. Results: MALAT1 was overexpressed in the newly diagnosed patients compared with post-treatment patients (mean ΔCT: -5.54 ± 0.16 vs. -3.84 ± 0.09, 3.25-fold change; p < 0.001) and healthy individuals (mean ΔCT: -5.54 ± 0.16 vs. -3.95 ± 0.21, 3.01-fold change; p < 0.001). The expression of MALAT1 strongly correlated with disease status, and the magnitude of change in MALAT1 post-treatment had prognostic relevance. The patients with early progression had a significantly smaller change in MALAT1 after treatment (mean ΔCT change: 1.26 ± 1.06 vs. 2.09 ± 0.79, p = 0.011). A cut-off value of the change in MALAT1 (ΔCT change: 1.5) was obtained, and the patients with a greater decrease in MALAT1 (difference in ΔCT >1.5) had significantly longer progression-free survival compared with the patients with a smaller MALAT1 change (24 months vs. 11 months; p = 0.001). For the post-treatment patients, the risk of early progression could be predicted using this cut-off value. Conclusions: MALAT1 was overexpressed in patients with myeloma and may play a role in its pathogenesis. In addition, MALAT1 may serve as a molecular predictor of early progression. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Cancer is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
